Revolution Medicines Inc. Insider Trading

RVMD

Last 12 months

Insiders sold $155M and bought nothing on the open market.

All of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Dec 2024.

Net open-market

−$155M

0 buys · 55 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

0 / 12

executives and directors

Last open-market buy

Dec 2024

Dec 5, 2024

Get an email when RVMD's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 26	Anthony Mancini See Remarks	Sold10b5-1 plan	2,310	$186.99	432K	5.5%	Form 4
Sep 29	Alan B. Sandler Chief Development Officer	Sold10b5-1 plan 5 parts	6,309	$202.14 average	$1.28M	11%	Form 4
Sep 25	Jeff Cislini SVP & General Counsel	Sold10b5-1 plan	765	$207.32	159K	1.5%	Form 4
Sep 24 – 25	Anthony Mancini See Remarks	Sold10b5-1 plan 2 parts	3,708	$200.45 average	743K	8.5%	Form 4
Sep 22	Elizabeth M Anderson Director	Sold10b5-1 plan 5 parts	10,143	$193.04 average	$1.96M	34%	Form 4
Sep 18	Anthony Mancini See Remarks	Sold10b5-1 plan	1,764	$196.94	347K	4.2%	Form 4
Sep 16	Anthony Mancini See Remarks	Sold10b5-1 plan 2 parts	1,774	$199.24 average	353K	4.0%	Form 4
Sep 16	Jeff Cislini SVP & General Counsel	Sold10b5-1 plan 2 parts	3,366	$199.23 average	671K	6.0%	Form 4
Sep 16	Alan B. Sandler Chief Development Officer	Sold10b5-1 plan 2 parts	341	$199.24 average	68K	0.6%	Form 4
Sep 16	Jack Anders Chief Financial Officer	Sold10b5-1 plan 2 parts	4,053	$199.24 average	808K	3.3%	Form 4
Sep 16	Stephen Michael Kelsey See Remarks	Sold10b5-1 plan 2 parts	5,569	$199.23 average	$1.11M	1.9%	Form 4
Sep 16	Margaret A Horn Chief Operating Officer	Sold10b5-1 plan 2 parts	4,967	$199.23 average	990K	3.2%	Form 4
Sep 16	Mark A Goldsmith See Remarks	Sold10b5-1 plan 2 parts	13,988	$199.23 average	$2.79M	4.3%	Form 4
Sep 11	Stephen Michael Kelsey See Remarks	Sold10b5-1 plan 8 parts	92,531	$202.36 average	$18.7M	24%	Form 4
Sep 10	Anthony Mancini See Remarks	Sold10b5-1 plan 5 parts	15,448	$204.16 average	$3.15M	26%	Form 4
Sep 8	Lorence H. Kim Director	Sold10b5-1 plan 7 parts	17,090	$209.82 average	$3.59M	93%	Form 4
Aug 31	Lorence H. Kim Director	Sold10b5-1 plan 7 parts	56,000	$203.24 average	$11.4M	75%	Form 4
Aug 21	Jeff Cislini General Counsel	Sold10b5-1 plan 6 parts	56,894	$209.24 average	$11.9M	50%	Form 4
Aug 21	Mark A Goldsmith See Remarks	Sold10b5-1 plan 18 parts	86,000	$209.20 average	$18M	18%	Form 4
Jun 29	Sushil Patel Director	Sold10b5-1 plan 9 parts	5,580	$187.99 average	$1.05M	20%	Form 4
Jun 24	Jack Anders Chief Financial Officer	Sold10b5-1 plan 4 parts	20,000	$168.33 average	$3.37M	14%	Form 4
Jun 16, 2025 – Jun 17	Margaret A Horn Chief Operating Officer	Sold10b5-1 plan 3 parts	93,575	$160.00 average	$15M	38%	Form 4
Jun 16	Anthony Mancini See Remarks	SoldNo plan	4,615	$156.12	720K	8.5%	Form 4
Jun 16	Mark A Goldsmith See Remarks	Sold10b5-1 plan	10,020	$156.12	$1.56M	2.9%	Form 4
Jun 16	Jeff Cislini General Counsel	Sold10b5-1 plan	2,157	$156.12	337K	3.7%	Form 4
Jun 16	Jack Anders Chief Financial Officer	Sold10b5-1 plan	2,722	$156.12	425K	2.2%	Form 4
Jun 16	Stephen Michael Kelsey See Remarks	Sold10b5-1 plan	4,175	$156.12	652K	1.4%	Form 4
Jun 11	Margaret A Horn Chief Operating Officer	Sold10b5-1 plan 7 parts	10,000	$148.01 average	$1.48M	5.9%	Form 4
May 26	Anthony Mancini See Remarks	Sold10b5-1 plan 3 parts	3,121	$153.99 average	481K	5.4%	Form 4
Apr 27	Anthony Mancini See Remarks	Sold10b5-1 plan 3 parts	3,120	$132.41 average	413K	5.4%	Form 4
Apr 15	Mark A Goldsmith See Remarks	Sold10b5-1 plan	120,000	$150.09	$18M	26%	Form 4
Mar 25	Anthony Mancini See Remarks	Sold10b5-1 plan 5 parts	37,450	$95.57 average	$3.58M	41%	Form 4
Mar 17 – 19	Jeff Cislini General Counsel	Sold10b5-1 plan 2 parts	2,958	$98.68 average	292K	4.8%	Form 4
Mar 17	Lin Wei Chief Medical Officer	Sold10b5-1 plan	2,073	$99.48	206K	2.0%	Form 4
Mar 17	Stephen Michael Kelsey See Remarks	Sold10b5-1 plan	4,302	$99.48	428K	1.4%	Form 4
Mar 17	Mark A Goldsmith See Remarks	Sold10b5-1 plan	12,871	$99.48	$1.28M	1.5%	Form 4
Mar 17	Margaret A Horn Chief Operating Officer	Sold10b5-1 plan	4,583	$99.48	456K	2.8%	Form 4
Mar 17	Jack Anders Chief Financial Officer	Sold10b5-1 plan	2,753	$99.48	274K	2.1%	Form 4
Mar 17	Xiaolin Wang See Remarks	Sold10b5-1 plan	2,010	$99.48	200K	1.7%	Form 4
Mar 2	Mark A Goldsmith See Remarks	Sold10b5-1 plan 13 parts	36,000	$101.23 average	$3.64M	7.9%	Form 4

Oct 2610b5-1 plan
Anthony Mancini
See Remarks · sold 2,310 at $186.99
432K
5.5% of stake
Sep 2910b5-1 plan
Alan B. Sandler
Chief Development Officer · sold 6,309 at avg $202.14
$1.28M
11% of stake
Sep 2510b5-1 plan
Jeff Cislini
SVP & General Counsel · sold 765 at $207.32
159K
1.5% of stake
Sep 24 – 2510b5-1 plan
Anthony Mancini
See Remarks · sold 3,708 at avg $200.45
743K
8.5% of stake
Sep 2210b5-1 plan
Elizabeth M Anderson
Director · sold 10,143 at avg $193.04
$1.96M
34% of stake
Sep 1810b5-1 plan
Anthony Mancini
See Remarks · sold 1,764 at $196.94
347K
4.2% of stake
Sep 1610b5-1 plan
Anthony Mancini
See Remarks · sold 1,774 at avg $199.24
353K
4.0% of stake
Sep 1610b5-1 plan
Jeff Cislini
SVP & General Counsel · sold 3,366 at avg $199.23
671K
6.0% of stake
Sep 1610b5-1 plan
Alan B. Sandler
Chief Development Officer · sold 341 at avg $199.24
68K
0.6% of stake
Sep 1610b5-1 plan
Jack Anders
Chief Financial Officer · sold 4,053 at avg $199.24
808K
3.3% of stake
Sep 1610b5-1 plan
Stephen Michael Kelsey
See Remarks · sold 5,569 at avg $199.23
$1.11M
1.9% of stake
Sep 1610b5-1 plan
Margaret A Horn
Chief Operating Officer · sold 4,967 at avg $199.23
990K
3.2% of stake
Sep 1610b5-1 plan
Mark A Goldsmith
See Remarks · sold 13,988 at avg $199.23
$2.79M
4.3% of stake
Sep 1110b5-1 plan
Stephen Michael Kelsey
See Remarks · sold 92,531 at avg $202.36
$18.7M
24% of stake
Sep 1010b5-1 plan
Anthony Mancini
See Remarks · sold 15,448 at avg $204.16
$3.15M
26% of stake
Sep 810b5-1 plan
Lorence H. Kim
Director · sold 17,090 at avg $209.82
$3.59M
93% of stake
Aug 3110b5-1 plan
Lorence H. Kim
Director · sold 56,000 at avg $203.24
$11.4M
75% of stake
Aug 2110b5-1 plan
Jeff Cislini
General Counsel · sold 56,894 at avg $209.24
$11.9M
50% of stake
Aug 2110b5-1 plan
Mark A Goldsmith
See Remarks · sold 86,000 at avg $209.20
$18M
18% of stake
Jun 2910b5-1 plan
Sushil Patel
Director · sold 5,580 at avg $187.99
$1.05M
20% of stake
Jun 2410b5-1 plan
Jack Anders
Chief Financial Officer · sold 20,000 at avg $168.33
$3.37M
14% of stake
Jun 16, 2025 – Jun 1710b5-1 plan
Margaret A Horn
Chief Operating Officer · sold 93,575 at avg $160.00
$15M
38% of stake
Jun 16No plan
Anthony Mancini
See Remarks · sold 4,615 at $156.12
720K
8.5% of stake
Jun 1610b5-1 plan
Mark A Goldsmith
See Remarks · sold 10,020 at $156.12
$1.56M
2.9% of stake
Jun 1610b5-1 plan
Jeff Cislini
General Counsel · sold 2,157 at $156.12
337K
3.7% of stake
Jun 1610b5-1 plan
Jack Anders
Chief Financial Officer · sold 2,722 at $156.12
425K
2.2% of stake
Jun 1610b5-1 plan
Stephen Michael Kelsey
See Remarks · sold 4,175 at $156.12
652K
1.4% of stake
Jun 1110b5-1 plan
Margaret A Horn
Chief Operating Officer · sold 10,000 at avg $148.01
$1.48M
5.9% of stake
May 2610b5-1 plan
Anthony Mancini
See Remarks · sold 3,121 at avg $153.99
481K
5.4% of stake
Apr 2710b5-1 plan
Anthony Mancini
See Remarks · sold 3,120 at avg $132.41
413K
5.4% of stake
Apr 1510b5-1 plan
Mark A Goldsmith
See Remarks · sold 120,000 at $150.09
$18M
26% of stake
Mar 2510b5-1 plan
Anthony Mancini
See Remarks · sold 37,450 at avg $95.57
$3.58M
41% of stake
Mar 17 – 1910b5-1 plan
Jeff Cislini
General Counsel · sold 2,958 at avg $98.68
292K
4.8% of stake
Mar 1710b5-1 plan
Lin Wei
Chief Medical Officer · sold 2,073 at $99.48
206K
2.0% of stake
Mar 1710b5-1 plan
Stephen Michael Kelsey
See Remarks · sold 4,302 at $99.48
428K
1.4% of stake
Mar 1710b5-1 plan
Mark A Goldsmith
See Remarks · sold 12,871 at $99.48
$1.28M
1.5% of stake
Mar 1710b5-1 plan
Margaret A Horn
Chief Operating Officer · sold 4,583 at $99.48
456K
2.8% of stake
Mar 1710b5-1 plan
Jack Anders
Chief Financial Officer · sold 2,753 at $99.48
274K
2.1% of stake
Mar 1710b5-1 plan
Xiaolin Wang
See Remarks · sold 2,010 at $99.48
200K
1.7% of stake
Mar 210b5-1 plan
Mark A Goldsmith
See Remarks · sold 36,000 at avg $101.23
$3.64M
7.9% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch RVMD, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with RVMD

CompareIntrinsic value

SRZNSurrozen, Inc.

$31.65+5.08%10

ELUTElutia Inc.

$0.76-6.52%20

RLAYRelay Therapeutics Inc.

$18.03+3.38%40

LCTXLineage Cell Therapeutics Inc.

$1.03+1.98%10

CRBUCaribou Biosciences, Inc.

$0.44-3.27%10

CRSPCrispr Therapeutics AG

$51.78+3.57%40

ALECAlector Inc.

$2.28+11.22%10

XFORX4 Pharmaceuticals Inc.

$3.24+2.21%20

Held by ETFs

RVMD is in 148 US ETFs. The largest of them, with RVMD's weight in each:

Spot a number that looks wrong? Check it in RVMD's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing RVMD

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.